Table 1.

Study design of eligible studies

Abbreviations: AUC, area under the curve; HT, hematological toxicities; NHT, nonhematological toxicities; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; RR, response rate.